Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Survival estimates in advanced terminal cancer

INTRODUCTION

Survival estimates are critical factors in physician and patient decision making in all phases of a serious and/or life-threatening illness. However, prognostic estimates in patients with advanced terminal cancer may have increased importance as they approach the end of life, since this is a natural time to formally reevaluate the goals of treatment, with palliative care becoming more prominent, and disease-directed therapy less so.

However, despite its importance, prognostication in advanced terminal cancer is imperfect. Physicians are typically optimistic in their estimates of patient survival, and the prognostic estimates they communicate to patients may be even more optimistic. In an effort to improve these estimates, investigators are integrating previously established prognostic factors into easy to use models that physicians can use in the clinical care of their patients with advanced terminal cancer. The goal of improved prognostication is to provide patients with a better understanding of their expected survival and thereby allow them to make informed medical and social choices regarding their treatment path at the end of life, whether disease-directed, palliative, or a combination of both [1,2].

Here we discuss general aspects of estimating survival in patients with advanced terminal cancer. Prognostic estimates and the factors that influence outcome in specific cancers are discussed in separate topic reviews that cover individual tumors.

ACCURACY OF SURVIVAL ESTIMATES

Survival estimates that physicians make, guided only by their intuition and clinical experience, are called formulated prognoses. In the clinical setting of advanced terminal cancer, these formulated estimates are usually incorrect and the direction of the error is almost always optimistic [3-10]. That is, physicians tend to believe their patients have longer to live than they actually do. The disparity in actual versus estimated survival varies in different studies (table 1) [3-7,11-17]. In an illustrative study, 343 physicians referring 468 patients to one of five Chicago-area hospices were asked to provide an estimate of their patient's prognosis ("What is your best estimate of how long this patient has to live?), and they compared these prognostic estimates with actual survival [6]. The median observed patient survival was 24 days, and the mean ratio of predicted to observed survival was 5.3.

Nevertheless, formulated prognoses are of value, particularly when integrated with other methods to estimate the length of remaining life [5,6,18,19]. As an example, in one study, multivariate regression models that included physicians' prognostic estimates were more accurate than models without physician input [20]. Thus, while it is true that statistical models can be more accurate than human intuition alone [20-22], it is also true that physicians provide important information that is not captured in the models alone.

         

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jun 2014. | This topic last updated: Aug 8, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Weeks JC, Cook EF, O'Day SJ, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 1998; 279:1709.
  2. Lee SJ, Fairclough D, Antin JH, Weeks JC. Discrepancies between patient and physician estimates for the success of stem cell transplantation. JAMA 2001; 285:1034.
  3. Evans C, McCarthy M. Prognostic uncertainty in terminal care: can the Karnofsky index help? Lancet 1985; 1:1204.
  4. Forster LE, Lynn J. Predicting life span for applicants to inpatient hospice. Arch Intern Med 1988; 148:2540.
  5. Maltoni M, Nanni O, Derni S, et al. Clinical prediction of survival is more accurate than the Karnofsky performance status in estimating life span of terminally ill cancer patients. Eur J Cancer 1994; 30A:764.
  6. Christakis NA, Lamont EB. Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study. BMJ 2000; 320:469.
  7. Glare P, Virik K, Jones M, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 2003; 327:195.
  8. Chow E, Davis L, Panzarella T, et al. Accuracy of survival prediction by palliative radiation oncologists. Int J Radiat Oncol Biol Phys 2005; 61:870.
  9. Gripp S, Moeller S, Bölke E, et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol 2007; 25:3313.
  10. Twomey F, O'Leary N, O'Brien T. Prediction of patient survival by healthcare professionals in a specialist palliative care inpatient unit: a prospective study. Am J Hosp Palliat Care 2008; 25:139.
  11. Parkes CM. Accuracy of predictions of survival in later stages of cancer. Br Med J 1972; 2:29.
  12. Heyse-Moore LH, Johnson-Bell VE. Can doctors accurately predict the life expectancy of patients with terminal cancer? Pall Med 1987; 1:165.
  13. Maltoni M, Pirovano M, Scarpi E, et al. Prediction of survival of patients terminally ill with cancer. Results of an Italian prospective multicentric study. Cancer 1995; 75:2613.
  14. Maltoni M, Nanni O, Pirovano M, et al. Successful validation of the palliative prognostic score in terminally ill cancer patients. Italian Multicenter Study Group on Palliative Care. J Pain Symptom Manage 1999; 17:240.
  15. Oxenham D, Cornbleet MA. Accuracy of prediction of survival by different professional groups in a hospice. Palliat Med 1998; 12:117.
  16. Chow E, Harth T, Hruby G, et al. How accurate are physicians' clinical predictions of survival and the available prognostic tools in estimating survival times in terminally ill cancer patients? A systematic review. Clin Oncol (R Coll Radiol) 2001; 13:209.
  17. Stockler MR, Tattersall MH, Boyer MJ, et al. Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. Br J Cancer 2006; 94:208.
  18. Viganò A, Dorgan M, Bruera E, Suarez-Almazor ME. The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer. Cancer 1999; 86:170.
  19. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999; 130:515.
  20. Knaus WA, Harrell FE Jr, Lynn J, et al. The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments. Ann Intern Med 1995; 122:191.
  21. Muers MF, Shevlin P, Brown J. Prognosis in lung cancer: physicians' opinions compared with outcome and a predictive model. Thorax 1996; 51:894.
  22. Lee KL, Pryor DB, Harrell FE Jr, et al. Predicting outcome in coronary disease. Statistical models versus expert clinicians. Am J Med 1986; 80:553.
  23. Hagerty RG, Butow PN, Ellis PM, et al. Communicating with realism and hope: incurable cancer patients' views on the disclosure of prognosis. J Clin Oncol 2005; 23:1278.
  24. Daugherty CK, Hlubocky FJ. What are terminally ill cancer patients told about their expected deaths? A study of cancer physicians' self-reports of prognosis disclosure. J Clin Oncol 2008; 26:5988.
  25. Lamont EB, Christakis NA. Prognostic disclosure to patients with cancer near the end of life. Ann Intern Med 2001; 134:1096.
  26. Zubrod GC, Schneiderman M, Frei E, et al. Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen and mustard and triethylene thiophosphoramide. J Chron Disease 1960; 11:7.
  27. Christakis NA. Timing of referral of terminally ill patients to an outpatient hospice. J Gen Intern Med 1994; 9:314.
  28. Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med 1988; 148:1586.
  29. Coates A, Porzsolt F, Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 1997; 33:1025.
  30. Allard P, Dionne A, Potvin D. Factors associated with length of survival among 1081 terminally ill cancer patients. J Palliat Care 1995; 11:20.
  31. Rosenthal MA, Gebski VJ, Kefford RF, Stuart-Harris RC. Prediction of life-expectancy in hospice patients: identification of novel prognostic factors. Palliat Med 1993; 7:199.
  32. Loprinzi CL, Laurie JA, Wieand HS, et al. Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol 1994; 12:601.
  33. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980; 45:2220.
  34. Mor V, Laliberte L, Morris JN, Wiemann M. The Karnofsky Performance Status Scale. An examination of its reliability and validity in a research setting. Cancer 1984; 53:2002.
  35. Hyde L, Wolf J, McCracken S, Yesner R. Natural course of inoperable lung cancer. Chest 1973; 64:309.
  36. McCusker J. The terminal period of cancer: definition and descriptive epidemiology. J Chronic Dis 1984; 37:377.
  37. Barbot AC, Mussault P, Ingrand P, Tourani JM. Assessing 2-month clinical prognosis in hospitalized patients with advanced solid tumors. J Clin Oncol 2008; 26:2538.
  38. Pirovano M, Maltoni M, Nanni O, et al. A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. Italian Multicenter and Study Group on Palliative Care. J Pain Symptom Manage 1999; 17:231.
  39. Morita T, Tsunoda J, Inoue S, Chihara S. Validity of the palliative performance scale from a survival perspective. J Pain Symptom Manage 1999; 18:2.
  40. Janisch L, Mick R, Schilsky RL, et al. Prognostic factors for survival in patients treated in phase I clinical trials. Cancer 1994; 74:1965.
  41. Lau F, Downing GM, Lesperance M, et al. Use of Palliative Performance Scale in end-of-life prognostication. J Palliat Med 2006; 9:1066.
  42. Llobera J, Esteva M, Rifà J, et al. Terminal cancer. duration and prediction of survival time. Eur J Cancer 2000; 36:2036.
  43. Anderson F, Downing GM, Hill J, et al. Palliative performance scale (PPS): a new tool. J Palliat Care 1996; 12:5.
  44. Components of the palliative performance scale (PPS) available online at http://pallipedia.org/term.php?id=504 (Accessed on March 14, 2011).
  45. Lau F, Maida V, Downing M, et al. Use of the Palliative Performance Scale (PPS) for end-of-life prognostication in a palliative medicine consultation service. J Pain Symptom Manage 2009; 37:965.
  46. Lau F, Downing M, Lesperance M, et al. Using the Palliative Performance Scale to provide meaningful survival estimates. J Pain Symptom Manage 2009; 38:134.
  47. Seow H, Barbera L, Dudgeon D, et al. The association of the palliative performance scale and hazard of death in an ambulatory cancer population. J Palliat Med 2013; 16:156.
  48. Downing M, Lau F, Lesperance M, et al. Meta-analysis of survival prediction with Palliative Performance Scale. J Palliat Care 2007; 23:245.
  49. Feinstein AR. Symptoms as an index of biological behaviour and prognosis in human cancer. Nature 1966; 209:241.
  50. Viganò A, Dorgan M, Buckingham J, et al. Survival prediction in terminal cancer patients: a systematic review of the medical literature. Palliat Med 2000; 14:363.
  51. Morita T, Tsunoda J, Inoue S, Chihara S. The Palliative Prognostic Index: a scoring system for survival prediction of terminally ill cancer patients. Support Care Cancer 1999; 7:128.
  52. Maltoni M, Caraceni A, Brunelli C, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol 2005; 23:6240.
  53. Tamburini M, Brunelli C, Rosso S, Ventafridda V. Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manage 1996; 11:32.
  54. Salpeter SR, Malter DS, Luo EJ, et al. Systematic review of cancer presentations with a median survival of six months or less. J Palliat Med 2012; 15:175.
  55. Chuang RB, Hu WY, Chiu TY, Chen CY. Prediction of survival in terminal cancer patients in Taiwan: constructing a prognostic scale. J Pain Symptom Manage 2004; 28:115.
  56. Martin L, Watanabe S, Fainsinger R, et al. Prognostic factors in patients with advanced cancer: use of the patient-generated subjective global assessment in survival prediction. J Clin Oncol 2010; 28:4376.
  57. Gwilliam B, Keeley V, Todd C, et al. Development of prognosis in palliative care study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. BMJ 2011; 343:d4920.
  58. Scarpi E, Maltoni M, Miceli R, et al. Survival prediction for terminally ill cancer patients: revision of the palliative prognostic score with incorporation of delirium. Oncologist 2011; 16:1793.
  59. Feliu J, Jiménez-Gordo AM, Madero R, et al. Development and validation of a prognostic nomogram for terminally ill cancer patients. J Natl Cancer Inst 2011; 103:1613.
  60. Maltoni M, Scarpi E, Pittureri C, et al. Prospective comparison of prognostic scores in palliative care cancer populations. Oncologist 2012; 17:446.
  61. Johnstone PA, Norton MS, Riffenburgh RH. Survival of patients with untreated breast cancer. J Surg Oncol 2000; 73:273.
  62. Kowalski LP, Carvalho AL. Natural history of untreated head and neck cancer. Eur J Cancer 2000; 36:1032.
  63. Attali P, Prod'Homme S, Pelletier G, et al. Prognostic factors in patients with hepatocellular carcinoma. Attempts for the selection of patients with prolonged survival. Cancer 1987; 59:2108.
  64. Cellerino R, Tummarello D, Guidi F, et al. A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991; 9:1453.
  65. Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000; 83:447.
  66. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27:145.
  67. Thongprasert S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999; 24:17.
  68. Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ 1993; 306:752.
  69. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378.
  70. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25.
  71. Keating JJ, Johnson PJ, Cochrane AM, et al. A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 1989; 60:789.
  72. Glimelius B, Ekström K, Hoffman K, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8:163.
  73. Chang VT, Hwang SS, Kasimis B, Thaler HT. Shorter symptom assessment instruments: the Condensed Memorial Symptom Assessment Scale (CMSAS). Cancer Invest 2004; 22:526.
  74. Glare PA, Eychmueller S, McMahon P. Diagnostic accuracy of the palliative prognostic score in hospitalized patients with advanced cancer. J Clin Oncol 2004; 22:4823.
  75. Chow E, Abdolell M, Panzarella T, et al. Predictive model for survival in patients with advanced cancer. J Clin Oncol 2008; 26:5863.
  76. Trédan O, Ray-Coquard I, Chvetzoff G, et al. Validation of prognostic scores for survival in cancer patients beyond first-line therapy. BMC Cancer 2011; 11:95.
  77. Tassinari D, Montanari L, Maltoni M, et al. The palliative prognostic score and survival in patients with advanced solid tumors receiving chemotherapy. Support Care Cancer 2008; 16:359.
  78. Christakis NA. Death foretold: Prophecy and Prognosis and Medical Care, University of Chicago Press, Chicago 1999.
  79. Poses RM, Bekes C, Winkler RL, et al. Are two (inexperienced) heads better than one (experienced) head? Averaging house officers' prognostic judgments for critically ill patients. Arch Intern Med 1990; 150:1874.